# PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug/ > **Published:** 2026-06-23T12:26:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:21:35-04:00 > **Clinical Summary:** PleoPharma Phase 3 trial advances cannabis withdrawal pharmacotherapy research. What clinicians need to know about emerging treatment options. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyNeurologyDosingIndustryAnxiety Why This Matters Clinicians treating patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) currently lack FDA-approved pharmacotherapy for withdrawal symptoms, making this Phase 3 trial significant for potentially expanding evidence-based treatment options. If successful, an approved cannabis withdrawal medication could improve treatment adherence and outcomes in patients experiencing withdrawal-induced relapse, particularly given the increasing prevalence of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder and higher potency products in the market. This development addresses a clinical gap where patients must rely on supportive care alone, enabling more comprehensive [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) similar to approaches available for opioid or alcohol withdrawal. Clinical Summary PleoPharma has initiated a Phase 3 clinical trial evaluating a novel pharmacological treatment for cannabis withdrawal syndrome, advancing toward potential FDA approval of the first medication specifically designed to address this indication. While cannabis withdrawal is increasingly recognized as a clinically significant condition characterized by irritability, sleep disturbance, anxiety, and mood changes in regular users attempting cessation, no FDA-approved medications currently exist to manage these symptoms, leaving clinicians with only supportive care strategies. Success in this Phase 3 trial could establish the first evidence-based pharmacological option for cannabis withdrawal, particularly relevant as [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorders have become more prevalent and as more patients seek help discontinuing use. The availability of an approved withdrawal treatment would enhance clinical capacity to support cannabis cessation and could improve outcomes for patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) who experience significant withdrawal symptoms that interfere with quit attempts. Clinicians should remain aware that this emerging therapeutic option may soon provide an additional tool for managing [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/), particularly for patients in whom behavioral interventions alone prove insufficient. Dr. Caplan’s Take “We’re seeing early signals that targeted pharmacotherapy for cannabis withdrawal could help certain patients, but Phase 3 trials are still running and we need to see the full efficacy and safety data before we know whether this will meaningfully change clinical practice. Until those results are published and reviewed, I’m cautiously watching this space rather than recommending it to patients.” Clinical Perspective 🧠 While cannabis withdrawal syndrome has gained recognition as a clinically meaningful condition affecting heavy users seeking abstinence, the development of pharmacologic treatments remains limited and the underlying [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) are not fully characterized. This Phase 3 trial represents a potentially important advance, though clinicians should note that efficacy data from earlier trial phases have not yet been publicly detailed, and the generalizability to diverse patient populations and concurrent substance use disorders remains unclear. Current clinical management of cannabis withdrawal typically relies on cognitive-behavioral support and symptomatic treatment (sleep aids, anxiolytics), which many patients manage successfully without pharmacotherapy. Should this agent demonstrate efficacy and safety in Phase 3, it would expand the toolkit for patients with severe withdrawal symptoms or multiple failed abstinence attempts, though its role relative to psychosocial interventions and in cost-benefit analysis will need careful evaluation once complete trial results are published. For now, clinicians should continue standard support 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20PleoPharma%20Begins%20Phase%203%20Trial%20for%20Cannabis%20Withdrawal%20Drug%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66404)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66404)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20PleoPharma%20Begins%20Phase%203%20Trial%20for%20Cannabis%20Withdrawal%20Drug%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D66404)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.mychesco.com/a/news/health-medical/research/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug/](https://www.mychesco.com/a/news/health-medical/research/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).